The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
IMMU-132, an SN-38 antibody-drug conjugate (ADC) targeting Τrop-2, as a novel platform for the therapy of diverse metastatic solid cancers: Clinical results.
Alexander Starodub
Research Funding - Immunomedics
Allyson J. Ocean
Research Funding - Immunomedics
Michael J. Guarino
Research Funding - Immunomedics
Vincent J. Picozzi
Research Funding - Immunomedics
Sajeve Samuel Thomas
No relevant relationships to disclose
Wells A. Messersmith
Research Funding - Immunomedics
Manish A. Shah
Research Funding - Immunomedics
Linda T. Vahdat
Research Funding - Immunomedics
Ellen Chuang
Research Funding - Immunomedics
Bruce S. Lin
Research Funding - Immunomedics
Serengulam V. Govindan
Stock Ownership - Immunomedics
Pius P Maliakal
Employment or Leadership Position - Immunomedics
William A. Wegener
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
Steven A. Hamburger
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics (I)
Robert M. Sharkey
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics
David M. Goldenberg
Employment or Leadership Position - Immunomedics
Stock Ownership - Immunomedics (B)